comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 23:33:38 - browse：65581

Pascal Soriot 2019 — Pascal Soriot has served as CEO of AstraZeneca since 2012. Win McNamee/Getty Images

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to build on its momentum in fields like oncology as it said it would nearly double its revenue to $80 billion by 2030.

Hitting such a target would depend on the launch of 20 new medicines and continued growth of its cancer and rare disease therapies, as well as other drugs. It would also require outpacing the targets laid out by AstraZeneca’s large pharma peers.

But at an investor day here at the company’s shiny new Discovery Centre, CEO Pascal Soriot opened his presentation by bringing up the goal set by the company a decade ago — $45 billion in revenue by 2023. The company faced some declines early in that period, but after surging in the past few years, it hit that target, bringing in $45.8 billion last year. Its recent growth has also propelled the company’s share price.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Biotech venture capitalists face new demands from investors

WSS

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Lindsay Lohan welcomes 1st child with husband Bader Shammas

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

My yearlong odyssey to get my son’s ADHD medication covered

Researchers separate signal from noise in heart wearable data

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

As demand for Covid shots wanes, Moderna seeks its next success

Researchers separate signal from noise in heart wearable data

Medical records are filled with copy

Why the Crimean Bridge is key to Russia's war in Ukraine

Medical records are filled with copy

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

New air purifier tech could be key to improving indoor air quality

How dance can help health care workers heal from trauma

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why the Crimean Bridge is key to Russia's war in Ukraine

Wikipedia

Francis Collins on trust in science and how Covid communications failed

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Copay coupons to count toward deductibles, after Biden court move

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Biotech venture capitalists face new demands from investors

Medicare Advantage today, explained in one chart

knowledge

entertainment

Wikipedia

focus